Shanghai Allink Biotherapeutics Co., Ltd.
4 clinical trials · Sponsor
◉ Watch Shanghai Allink Biotherapeutics Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants. (NCT07742956) | Shanghai Allink Biotherapeutics Co., Ltd. | 2026-08-20 |
| Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. (NCT07603791) | Shanghai Allink Biotherapeutics Co., Ltd. | 2026-06-30 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors (NCT06707610) | Shanghai Allink Biotherapeutics Co., Ltd. | 2025-02-10 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors (NCT06656390) | Shanghai Allink Biotherapeutics Co., Ltd. | 2024-10-24 |
Track Shanghai Allink Biotherapeutics Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.